Product Specifications for Recombinant Mouse VLDLR (Ser297) Protein, CF
Mouse myeloma cell line, NS0-derived mouse VLDL R protein Thr25-Ala798, with a C-terminal 10-His tag
>85%, by SDS-PAGE under reducing conditions and visualized by silver stain
<0.10 EU per 1 μg of the protein by the LAL method.
N-terminal sequence Analysis
Predicted Molecular Mass
130-175 kDa, reducing conditions
Measured by its binding ability in a functional ELISA.
When Recombinant Mouse LRPAP (Catalog # 4480-LR) is coated at 1 μg/mL (100 μL/well), the concentration of Recombinant Mouse VLDL R that produces 50% of the optimal binding response is found to be approximately 0.01‑0.05 μg/mL.
Alternately, when Recombinant Mouse VLDL R is coated at 2.5 μg/mL (100 μL/well), the concentration of Recombinant Mouse Reelin (Catalog # 3820-MR) that produces 50% of the optimal binding response is found to be approximately 0.5-2.5 μg/mL.
Formulation, Preparation and Storage
What does CF mean?
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our
Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant
protein to be stored at a more dilute concentration.
The carrier free version does not contain BSA.
What formulation is right for me?
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or
as an ELISA standard.
In contrast, the carrier free protein is recommended for applications, in which the presence of BSA
Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitute at 100 μg/mL in sterile PBS.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
3 months, -20 to -70 °C under sterile conditions after reconstitution.
VLDL R is a 130 kDa type I transmembrane protein in the LDL receptor family that plays a significant role in lipid metabolism and in nervous system development and function (1, 2). Mouse VLDL R has a 774 aa extracellular domain (ECD) (aa 25 ‑ 798) and a 54 aa cytoplasmic domain. The ECD contains eight LDLR class A repeats, three EGF‑like domains, six LDLR class B repeats, and a juxtamembrane region that is rich in O‑linked glycosylation (3, 4, 5). The cytoplasmic domain contains one NPXY internalization motif. Mouse VLDL R has at least one 105 kDa alternative splice form. This variant (termed type II VLDL R) shows an Arg substitution for aa 751 ‑ 779, and has been associated with endothelial cells (5, 6). The VLDL R expressed here corresponds to a polymorphic form that shows a Cys at position 297 of the precursor. This generates a disulfide bond in the 7th LDL class A domain that is not present when position 297 is occupied by Ser (SwissProt # P98156). The 7th domain is suggested to be a critical determinant of apoE binding to VLDL R (7). VLDL R is predominantly expressed in striated muscle, adipose tissue, brain, and endothelial cells lining capillaries and small arterioles (3, 4, 8, 9). VLDL R participates in the tissue uptake of fatty acids from plasma by mediating the internalization of ApoE‑containing lipoparticles (i.e. VLDL, beta ‑VLDL, and chylomicron remnants) (8, 10). VLDL R binds and internalizes lipoprotein lipase (LPL) and mediates its transport from the basolateral to the lumenal face of endothelial cells (9, 11). VLDL R knockout mice are characterized by reduced LPL activity, reduced serum triglyceride clearance, and a resistance to developing obesity (10, 12, 13). VLDL R influences breast cancer cell motility by mediating the uptake of uPAR‑PAI1 complexes (9, 14). Lipoprotein accumulation via macrophage VLDL R is instrumental in promoting the formation of atherosclerotic plaques (15). In the nervous system, VLDL R and ApoE R2 interactions with reelin are critical for neuronal migration and positioning in the developing brain (16). VLDL R also functions in adult hippocampal synapse maturation, synaptic plasticity, and memory formation (17, 18). The ECD of mouse VLDL R shares 95% aa sequence identity with human and rat VLDL R. Within shared regions, mouse VLDL R shares 55% and 53% aa sequence identity with ApoE R2 and LDL R, respectively.
Qiu, S. et al. (2006) Neurobiol. Learn. Mem. 85:16.
May, P. et al. (2005) Cell. Mol. Life Sci. 62:2325.
Gafvels, M.E. et al. (1994) Endocrinology 135:387.
Oka, K. et al. (1994) Eur. J. Biochem. 224:975.
Martensen, P.M. et al. (1997) Eur. J. Biochem. 248:583.
GenBank Accession # NP_001154892.
Ruiz, J. et al. (2005) J. Lipid Res. 46:1721.
Wyne, K.L. et al. (1996) Arterioscler. Thromb. Vasc. Biol. 16:407.
Argraves, K.M. et al. (1995) J. Biol. Chem. 270:26550.
Goudriaan, J.R. et al. (2001) Arterioscler. Thromb. Vasc. Biol. 21:1488.
Obunike, J.C. et al. (2001) J. Biol. Chem. 276:8934.
Yagyu, H. et al. (2002) J. Biol. Chem. 277:10037.
Goudriaan, J.R. et al. (2004) J. Lipid Res. 45:1475.
Webb, D.J. et al. (1999) J. Biol. Chem. 274:7412.
van Eck, M. et al. (2005) Atherosclerosis 183:230.
Jossin, Y. et al. (2004) J. Neurosci. 24:514.
Niu, S. et al. (2004) Neuron 41:71.
Weeber, E.J. et al. (2002) J. Biol. Chem. 277:39944.
Very Low Density Lipoprotein Receptor
Entrez Gene IDs
7436 (Human); 22359 (Mouse)
CARMQ1, CHRMQ1, FLJ35024, VLDL R, VLDL receptor, VLDL-R, VLDLR, VLDLRCH, very low density lipoprotein receptor, very low-density lipoprotein receptor
Which Brands are Currently Available on bio‑techne.com? R&D Systems, Tocris Bioscience and ProteinSimple branded products are available to purchase through bio‑techne.com. ProteinSimple branded instruments are available to quote. ACD branded products will be available on bio‑techne.com in the near future. Novus Biologicals branded products are not currently available on bio‑techne.com and can be found at novusbio.com.
Setting the standard in quality research reagents for over 30 years
A trusted leader in quality life science reagents
Your trusted supplier for innovative and high performance life science reagents
Proprietary systems and consumables for simpler, more quantitative and affordable protein analysis
Proprietary RNAscope® technology capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity
A world leader in developing liquid biopsy based diagnostics